TISIDB

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Secreted
Domain	PF08742 C8 domain PF13330 Mucin-2 protein WxxW repeating region PF01826 Trypsin Inhibitor like cysteine rich domain PF00094 von Willebrand factor type D domain
Function	Gel-forming glycoprotein of gastric and respiratoy tract epithelia that protects the mucosa from infection and chemical damage by binding to inhaled microrganisms and particles that are subsequently removed by the mucocilary system.

> Gene Ontology [ TOP ]
Biological Process	GO:0001894 tissue homeostasis GO:0006486 protein glycosylation GO:0006493 protein O-linked glycosylation GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0016266 O-glycan processing GO:0030198 extracellular matrix organization GO:0036438 maintenance of lens transparency GO:0043062 extracellular structure organization GO:0043206 extracellular fibril organization GO:0043413 macromolecule glycosylation GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048871 multicellular organismal homeostasis GO:0060249 anatomical structure homeostasis GO:0070085 glycosylation GO:0097435 fibril organization
Molecular Function	GO:0005201 extracellular matrix structural constituent
Cellular Component	GO:0005578 proteinaceous extracellular matrix GO:0005796 Golgi lumen GO:0043205 fibril GO:0044420 extracellular matrix component

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5621481: C-type lectin receptors (CLRs) R-HSA-5621480: Dectin-2 family R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS) R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1) R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC) R-HSA-1643685: Disease R-HSA-3906995: Diseases associated with O-glycosylation of proteins R-HSA-3781865: Diseases of glycosylation R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-392499: Metabolism of proteins R-HSA-5173105: O-linked glycosylation R-HSA-913709: O-linked glycosylation of mucins R-HSA-597592: Post-translational protein modification R-HSA-977068: Termination of O-glycan biosynthesis

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5621480: Dectin-2 family
R-HSA-5083632: Defective C1GALT1C1 causes Tn polyagglutination syndrome (TNPS)
R-HSA-5083636: Defective GALNT12 causes colorectal cancer 1 (CRCS1)
R-HSA-5083625: Defective GALNT3 causes familial hyperphosphatemic tumoral calcinosis (HFTC)
R-HSA-1643685: Disease
R-HSA-3906995: Diseases associated with O-glycosylation of proteins
R-HSA-3781865: Diseases of glycosylation
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-5173105: O-linked glycosylation
R-HSA-913709: O-linked glycosylation of mucins
R-HSA-597592: Post-translational protein modification
R-HSA-977068: Termination of O-glycan biosynthesis

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MUC5AC and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between MUC5AC and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
16778191	Breast Carcinoma	Inhibit immunity (T cell function)	Different progression of tumor xenografts between mucin-producing and mucin-non-producing mammary adenocarcinoma-bearing mice. tumor formation by using mucin-producing (TA3-Ha) and mucin-non-producing (TA3-St) cloned variants of mouse mammary adenocarcinomas. IFN-gamma-producing CD4 T cells in spleens obtained from TA3-Ha tumor-bearing mice were significantly reduced compared with TA3-St tumor-bearing mice, suggesting that mucins cause PGE2-mediated immune suppression.
29625896	hepatocellular carcinoma	Inhibit immunity (infiltration)	Putative B7S1 receptor was co-expressed with PD-1 but not T cell immunoglobulin and mucin-domain containing-3 (Tim-3) at an activated state of early tumor-infiltrating CD8+ T cells, and B7S1 promoted T cell exhaustion, possibly through Eomes overexpression.

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MUC5AC in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MUC5AC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.593	0.409
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.726	0.174
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.831	0.556
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.058	0.889
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.058	0.927
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.936	0.0795

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MUC5AC in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	14.8	-12.2	0.151
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	23.1	-18.6	0.134
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MUC5AC. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MUC5AC. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MUC5AC. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MUC5AC. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MUC5AC expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MUC5AC and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MUC5AC
Name	mucin 5AC, oligomeric mucus/gel-forming
Aliases	mucin 5, subtypes A and C, tracheobronchial/gastric; TBM; leB; mucin; gastric mucin; lewis B blood group ant ......
Chromosomal Location	11p15.5
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MUC5AC collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MUC5AC